Rezera, a clinical-stage biotechnology company developing oral NLRP3 inhibitors for inflammatory diseases, announced terms for its initial public offering on Thursday, November 5, 2026. The Boston-based company plans to raise $200 million by offering 16.7 million shares at a proposed price range of $11 to $13 per share. New investor GSK and an affiliate have indicated interest in purchasing up to $25 million of the offering, representing approximately 13% of the deal.
At the midpoint of the proposed range, Rezera would have a fully diluted market valuation of approximately $254 million. The company expects to price its IPO during the week of November 9, 2026.
Company Background
Founded in 2016, Rezera is developing oral inhibitors of NLRP3, a target described by the company as an upstream driver of sterile inflammation. Its research focuses on cardiovascular and neuroinflammatory diseases, with a pipeline that includes candidates at different stages of clinical development.
The company retains worldwide rights to all of its drug candidates, giving it control over the development and commercialization opportunities associated with its pipeline.
IPO Details and Institutional Participation
Rezera plans to list on the Nasdaq under the ticker symbol RZRA. The proposed offering consists of 16.7 million shares priced between $11 and $13, with expected gross proceeds of approximately $200 million.
GSK, together with an affiliate, has indicated interest in purchasing up to $25 million of the IPO. The potential investment represents approximately 13% of the offering and provides a notable institutional participation component.
Jefferies, TD Securities, and Cantor Fitzgerald are serving as joint bookrunners for the transaction.
Clinical Pipeline and Development Strategy
Rezera’s lead candidate, ruvonoflast, is an oral NLRP3 inhibitor that has completed two Phase 2 trials in cardiometabolic disease. The company plans to initiate a Phase 3 trial in peripheral artery disease during the first half of 2027, with results expected in 2028.
Its second candidate, trabzanoflast, is a brain-penetrant NLRP3 inhibitor that has completed a Phase 1 trial. Rezera is developing the compound for neuroinflammatory indications, extending its research beyond cardiovascular disease.
The company’s development strategy centers on targeting NLRP3 across multiple inflammatory conditions. However, the candidates remain subject to further clinical evaluation, and the planned Phase 3 program for ruvonoflast represents an important upcoming development milestone.
Market Opportunity and Risks
Rezera’s proposed IPO comes with a pipeline focused on inflammatory diseases and a lead candidate approaching late-stage clinical development. The planned Phase 3 trial for peripheral artery disease could represent a significant step in determining the clinical potential of ruvonoflast.
The proposed investment from GSK also represents a meaningful component of the offering, although the indicated participation does not guarantee that the full amount will be purchased.
As a clinical-stage biotechnology company, Rezera faces the development and regulatory uncertainties associated with advancing investigational therapies. The future value of its pipeline will depend on clinical results, subsequent development progress, and the ability to meet regulatory requirements.
Closing Insights
Rezera’s proposed $200 million IPO will provide public-market investors with exposure to a biotechnology company developing oral NLRP3 inhibitors for cardiovascular and neuroinflammatory diseases. The company’s next major milestone is the planned initiation of a Phase 3 trial for ruvonoflast in peripheral artery disease in the first half of 2027. Investors will also assess the final IPO pricing, GSK’s participation, and the company’s progress toward its anticipated 2028 clinical readout.
